On the evening of April 29, Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) released the annual report for 2021, realizing an operating revenue of 6.177 billion yuan, a year-on-year increase of 9.19%; The net profit was 1.248 billion yuan, a year-on-year increase of 38.42%. In addition, Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) plans to distribute a cash dividend of RMB 0.3 (including tax) to all shareholders for every 10 shares.
The annual report shows that thanks to the layout of the big health industry, Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) health pension, biological immunity and other businesses have developed well. During the reporting period, the operating revenue of big health business was 5.232 billion yuan, accounting for 84.70% of the total operating revenue.
The scale of health care industry continued to increase
Ankangtong, founded in 1998, is an old brand comprehensive elderly care service provider under Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) banner. According to the annual report of 2021, the number of successful bidders and business scale of ankangtong have increased year-on-year, with 10 new business coverage cities across the country. On the basis of deepening the original business, ankangtong has fully deployed the director’s insurance business, actively expanded the business of small and micro institutions and “family pension beds”, and explored the service mode of real estate and pension.
Ankangtong subsidiary Hekang focuses on home community institutional elderly care, opens up more than ten new markets and realizes the industrial development of brand chain. In terms of the development of the technical platform, the smart e + comprehensive service platform was launched, and several new modules such as Party Construction + pension system, time bank, meal assistance system and mutual pension were developed and successfully implemented in many places. Ankangtong and Hekang have been ranked among the top ten brands of smart elderly care in China.
The company has maintained a healthy and stable business for one year. In the future, under the background of accelerating population aging and national policy support, the company will fully integrate existing service resources, actively expand business layout and effectively improve service quality.
Boost the development of the whole industry chain of stem cells
According to the annual report of 2021, Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) continues to strengthen and consolidate the collection and storage of upstream stem cells, increase the research and development of midstream stem cell technology, promote the application of downstream stem cell therapy, develop business supplements of other products, create a customer service model integrating pre-sales, in-sales and after-sales services, and implement diversified development strategies.
The company increased its R & D efforts, and the Shanghai R & D center was officially put into operation in 2021; Successfully completed the filing of one stem cell project with Shenzhen People’s hospital. At the same time, actively try to expand the field, constantly explore the company’s new development model, further promote the development of the whole industry chain of stem cells and continuously improve the company’s value.
At present, the Shandong Cord Blood Bank operated and managed by the company is one of the seven cord blood banks approved and accepted by the national health administrative department. It is also the only legal cord blood preservation institution in Shandong Province.
Actively layout cdmo business
As a pioneer in the field of cellular immunity, dendreon has more than 15 years of research and development experience in cell therapy for mcrpc patients. The 2021 annual report shows that Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) continues to strengthen the product positioning of Provenge as the first-line therapy for patients with early asymptomatic or mild symptoms of mcrpc. Actively promote the research on early indications of prostate cancer. According to the current progress, the project is advancing according to the plan. It is expected that the application for expanding early indications will be formally submitted to FDA based on the results of provent test in the second half of 2023. The modernization of antigen process was officially submitted to FDA by Fuji in December 2020. The trial production was successful in 2021, which effectively improved the production efficiency. At the same time, based on its rich cell therapy operation experience and perfect commercialization ability, actively layout cdmo business, promote the industrialization development of cell immunotherapy, and broaden the introduction channels of pipeline products.
Than Shwe China submitted the application for clinical trial of Provenge (sipuleucel-t) (hereinafter referred to as ind application) and obtained the implied license for clinical trial from the drug evaluation center (CDE) of the State Drug Administration on August 5, 2020. During the reporting period, Than Shwe China has completed the construction and qualification certification of qPCR laboratory and is fully promoting the clinical trial process of Provenge.
It is reported that immunotherapy has the advantages of good curative effect, less toxic and side effects and prevention of recurrence in cancer treatment. It is known as the third revolution in tumor treatment after traditional chemotherapy drugs and targeted therapy. The company said that in the future, it will expand the coverage of registered patients, strengthen the management of channel parties, and provide better services for patients, doctors and agents; Improve team marketing ability and improve the conversion rate of registered patients. Continue to promote the application and listing process of products in China, pay attention to R & D pipelines, promote the expansion of early indications of Provenge, and expand the application scope of existing patents.
